Cargando…

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib

Small molecules targeting the EGFR tyrosine kinase domain have been used with some success at treating patients with non-small cell lung cancer driven by activating mutations in the kinase domain. The initial class of inhibitors displaced ATP noncovalently but were rendered ineffective due to the de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kannan, Srinivasaraghavan, Pradhan, Mohan R., Tiwari, Garima, Tan, Wei-Chong, Chowbay, Balram, Tan, Eng Huat, Tan, Daniel Shao-Weng, Verma, Chandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431542/ https://www.ncbi.nlm.nih.gov/pubmed/28484248 http://dx.doi.org/10.1038/s41598-017-01491-z

Ejemplares similares

Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2018)

Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules
por: Sutiman, Natalia, et al.
Publicado: (2016)

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Jain, Amit, et al.
Publicado: (2015)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Small Molecules Targeting the Inactive Form of the Mnk1/2 Kinases
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2016)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

Activation of p53: How phosphorylated Ser15 triggers sequential phosphorylation of p53 at Thr18 by CK1δ
por: Nicolaou, Sonia T., et al.
Publicado: (2022)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
por: Nishiya, Naoyuki, et al.
Publicado: (2019)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
por: Hirsh, Vera
Publicado: (2015)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
por: Pradhan, Mohan R, et al.
Publicado: (2019)

The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus – evolved or yet to evolve
por: Budhraja, Anshul, et al.
Publicado: (2021)

Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
por: Wong, Yee Hwa, et al.
Publicado: (2018)

Multimodal epidermal devices for hydration monitoring
por: Krishnan, Siddharth, et al.
Publicado: (2017)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
por: Sano, Kazumi, et al.
Publicado: (2020)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018)

Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial
por: Leung, Ying-Ying, et al.
Publicado: (2015)

A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases
por: Zeller, Matthias, et al.
Publicado: (2017)

The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma
por: Shu, Wenying, et al.
Publicado: (2022)

Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2021)

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
por: Kimura, Shinichi, et al.
Publicado: (2018)

Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC)
por: Fong, Pei Yuan, et al.
Publicado: (2019)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
por: Ma, Jun, et al.
Publicado: (2023)

A New Generation of Arachidonic Acid Analogues as Potential Neurological Agent Targeting Cytosolic Phospholipase A(2)
por: Ng, Cheng Yang, et al.
Publicado: (2017)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mbvtv3s6dipe3u9tmp5juqs38l